Subject index to volume 30
Subject index to volume 30
Symbols
2-Octyl cyanoacrylate
bonding strength of, 20, 23
description, 21
leak incidence, 22
leaking pressure, 22
A
A-scan biometry
measurement of axial length with, 24
ABK. See aphakic bullous keratopathy
Abscess
orbital
associated factors, 31
computed tomography findings, 30
presenting signs, 31
ACIOL. See anterior chamber, intraocular lens
Acrysof, 183
Acute severe visual-acuity decrease, 55, 57
ADD-V, 50
Age
as risk factor for POAG, 154, 156, 157
association with diabetic retinopathy, 180
Age-related macular degeneration, 46
cause of irreversible central visual loss, 116
description, 47
incidence of lesion, 59
neovascular
absence of effective treatment for, 58
geographic atrophy, 47
treatment with photodynamic therapy, 47
Age-related maculopathy, 47
Agency for Healthcare Research and Quality, 92
Alcohol consumption
association with POAG, 156
Allograft
dehydrated human-amniotic-membrane
compared with conjunctival autograft, 166
description, 167
grafting after pterygium excision, 166
transplantation after pterygium excision, 168
Alpha agonists, 162
AmbioDry. See allograft, dehydrated human-amnioticmembrane
Amikacin, 173
Aminoglycosides, 173
Angiogenesis
inhibition by TTT, 118
Angiography
confocal indocyanine green, 54
in RPED, 118
Angle
permanent closure, 164
Anterior chamber
inflammation, 182
intraocular lens, association with uveitis, glaucoma,
corneal decompensation, 183
involvement in glaucoma secondary to retinoblstoma,
127
watertight
maintenance in corneal perforations, 21
Antibiotics
for preseptal and orbital cellulitis, 28, 31, 33
for bacterial endophthalmitis, 173
for treatment of endophthalmitis, 18
intravitreal injection of, 18
Antibiotic Prophylaxis for Cataract Surgery, 87
Aphakic bullous keratopathy
indication for penetrating keratoplasty, 148-151
Aphakic correction, 182
Apoptosis
caused by TTT, 118
Argon laser trabeculoplasty, 162
ARMD. See age-related macular degeneration
Asia Pacific Congress of Ophthalmology, 6
Aspirin
association with POAG, 157
Asthma
association with orbital cellulitis, 32
Astigmatism
correction with laser, 75
ASVAD. See acute severe visual-acuity decrease
Autograft
conjunctival
after pterygium excision, 167
compared with allograft, 166
recurrence rate, 167
Axial length
measured with corneal diameter and slope, A-scan
biometry, 24, 26-27
role in IOL-power estimation, 25
Cornea
length measurement, 24
measured with A-scan, 26
B
B-zone peripapillary atrophy
association with glaucoma, 158
Bacteria
infections associated with orbital and preseptal
cellulitis, 33
Baltimore Eye Survey, 154
Bare-sclera resection
for excision of primary pterygium, 88
for pterygium, risk of recurrence, 90
with mitomycin C, 90
Beaver Dam Eye Study, 155
Behcet’s disease, 39, 40
BES, 155
beta-blockers 162, 163
Biometry
use in cataract surgery, 25
Blepharoplasty, 13
Blindness
bilateral, due to glaucoma, 162
caused by uveitis, 37
leading cause of, 154
National Prevention Program, 6
national survey in the Philippines, 154
population-based survey, 98
prevention of, 97
Third National Survey on, 162
Blood pressure
decrease after administration of tropicamidephenylephrine and tropicamide-phenylephrine, 9
diastolic, changes after administration of
tropicamide-phenylephrine and tropicamidephenylephrine, 10
effect of tropicamide-phenylephrine and
tropicamide-phenylephrine, 7
systolic, increase after phenylephrine administration,
8
Bone resorption
in cholesterol granuloma, 132
Brachytherapy
for intraocular retinoblastoma, 78
Bruch’s membrane
beaks in, 118
degeneration of, 118
sealing the break in, 116
Bullous keratopathy
indications for penetrating keratoplasty, 148
C
Carbonic anhydrase inhibitors, 162, 163
Cataract
complication of uveitis, 38, 40
evidence-based review of clinical practice guidelines,
91
surgery complications, 63
surgery in diabetic retinopathy, macular edema, 65
Cataract
leading cause of blindness, 154
management in patients with diabetes mellitus, 65
prevention of postoperative endophthalmitis, 85
risk of development in diabetic patients, 63
surgery
estimation of IOL power, 25
Cavernous sinus thrombosis
associated factors, 31
computed-tomography findings, 30
organisms involved in, 30
presenting signs, 31
Cellulitis
complications, 32
orbital
causative agents, 28, 29
clinical patterns, 28, 29
complications, 29
computed-tomography findings, 30
etiology, 28
management, 28, 29
organisms involved, 30
presenting signs, 31
profile of cases in the Philippines, 32
signs and symptoms, 32
surgical intervention for, 30, 33
preseptal
antibiotic treatment for, 31
associated factors, 29
causative agents, 28, 29
clinical patterns, 28, 29
complications, 29
etiology, 28
management, 28, 29
predisposing factors, 32
presenting signs, 28
profile of cases in the Philippines, 32
surgical interventon for, 33
Central-visual-field function, 53
Cerebrospinal fluid, 19
Chemoreduction
with adjuvant therapy for retinoblastoma, 79
for treatment of retinoblastoma, 80
Chemotherapy
for intraocular retinoblastoma, 78
for treatment of intraocular tumors, 81
Chemothermotherapy
for intraocular retinoblastoma, 78
Chlorhexidine
binding to the corneal epithelium, 121
cytotoxic activity of, 123
efficacy in treatment of keratomycosis, 120
for treatment of filamentous keratomycosis, 119
preparation of 0.2% solution, 120
safety as treatment for keratomycosis, 123
toxicity
in cornea, adjacent structures, 119, 120
Cholesteatoma
distinguished from cholesterol granuloma, 132
Cholesterol
association with diabetic retinopathy, 180
Cholesterol granuloma, 129
clinical, radiologic, histopathologic features of, 130
distinguished from
acute subperiosteal hematomas, 132
epidermoid cholesteatoma, 132
pathogenesis of, 130
presence of bone resorption in, 132
Choroidal melanoma
enucleation, 133
pathogenesis of, 133
Choroidal neovascular membrane
presence in RPED, 118
Choroidal neovascularization
classic
proportion of lesion, 53
reduction in the risk of vision loss, 53
in RPED
development, 116
progression, 117
occult
evidence from the TAP trial, 52
risk of visual acuity loss in, results from TAP trial, 53
CNV. See choroidal neovascularization
Coats’ disease
association with iris neovascularization, 127
Cochrane Central Register of Controlled Trials, 46, 62,
63, 79, 91
Colvard infrared pupilometer, 35
Combined cataract extraction, 162
Comod eye-drop dispenser, 140
Computed tomography
use in orbital and preseptal cellulitis, 33
Confocal indocyanine green, 54
Conjunctival autografting
for excision of primary pterygium, 88
Conjunctival hyperemia
with latanoprost use, 84
Contrast sensitivity
outcome from the TAP trial, 53
Cornea
diameter, slope, 25
lacerations and perforations
causes of, 21
sealing
use of fibrin glue, 21
use of sutures, 21
treatment options, 21
treatment with 2-Octyl cyanoacrylate, 21
processed and distributed by SLIEBF, 149
toxicity of chlorexidine in, 119
Corneal dystrophies, 149
Corneal edema, 182
Corneal scar
age distribution of cases, 151
association with trauma, 151
incidence peak, 151
indication for penetrating keratoplasty, 148, 149, 150
Corneal stromal dystrophy
indication for penetrating keratoplasty, 149
Corneal transplantation, 146
See also
Eye Bank Foundation of the Philippines
Republic Act 7885
Cryotherapy
For intraocular retinoblastoma, 78
Cup-disc ratio
basis for glaucoma diagnosis, 165
Cyanoacrylate adhesives, 21
Cyanoacrylate derivatives
histotoxic effects, 21
Cystoid macular edema
complication of uveitis, 38
D
Dehiscence, 170
Diabetes mellitus
association with
diabetic retinopathy, 178, 180
orbital cellulitis, 32
POAG, 156, 158
global prevalence of, 63
risk factor for
endophthalmitis, 138
glaucoma, 154
Diabetic retinopathy
association with
age, 180
cholesterol levels, 180
fasting blood glucose, 180
glycosylated hemoglobin, 180
medication, 180
sex, 180
smoking, 180
cause of blindness, 179
clinical and angiographic prevalence rates, 178, 180
correlation with visual outcome, 63
grading system, 179
nonproliferative, proliferative, 179
prevalence
according to fundus examination, 178
among diabetic patients, 178
rates, 179, 180
progression
after phacoemulsification, 65
effect of phacoemulsification on, 62
in diabetic patients, 63
postoperative, 64
Diode cyclo-photocoagulation, 162
Disc hemorrhage
pevalence in glaucoma, 158
DM. See diabetes mellitus
DR. See diabetic retinopathy
Dystrophy
Corneal stromal
indications for penetrating keratoplasty, 148
Fuch’s
indications for penetrating keratoplasty, 148
E
EBFP. See Eye Bank Foundation of the Philippines
EBM. See Evidence-based medicine
Electroretinogram, 174
Endophthalmitis
after cataract surgery, 137
association with scleral fixation, 183
bacterial, treatment of, 172, 173, 177
blurring of vision in, 137
diagnosis, 137
pain in, 137
preferred treatment, 18
postoperative, prevention of 85
rising trend in, 87
risk facors for, 138
treatment, 137, 138
treatment with pars plana vitrectomy, 137
treatment and prevention of, 19
Endophthalmitis Vitrectomy Study, 137, 139, 173
Epidemiology
of blindness in the Philippines, 98
Epithelialization
in chlorhexidine-treated rabbit eyes, 121
ERG. See Electroretinography
Evidence-Based Clinical Practice Guidelines for the
Management of Cataract among Adults, 92
Evidence-based medicine
application in ophthalmology, 73
five steps in the practice of, 74
limitations of, 74
significance in clinical practice, 44
Excimer laser, 77
Exophthalmos, 12
Extracapsular cataract extraction
compared with manual small-incision surgery, 91
review of guidelines, 91-92
visual outcome among diabetic patients, 63
Extracapsular surgery, 45
Eye health
policies, 98
promotion of, 4
research in, 97
Eye Bank Foundation of the Philippines, 146
Eye banking
obstacles to, 145
Philippine experience, 145
F
Fasting blood glucose
association with diabetic retinopathy, 180
Fat debulking, 13, 15
Fibrin glue
description of, 167
success rates in conjunctival autografts, 167
use in sealing corneal perforations, 21
Fibrosis
in upper-eyelid retraction, 15
Filtration surgery, 163
Fluoroquinolones, 19
Fuch’s dystrophy 148-151
Fundus
findings in optic neuritis, 68
G
Gentamicin
for prevention of postoperative endophthalmitis, 87
toxicity of intravitreal injection, 173
Glaucoma
association with ACIOL, 183
association with IOP, 158
cause of
bilateral blindness in the Philippines, 162
low vision in the Philippines, 162
visual impairment in the Philippines, 154
clinical presentation in retinoblastoma, 125
common types seen in a tertiary hospital, 163
complication of uveitis, 38, 40
diagnosis in early stages, 154
drainage-device implantation, 162
effect of age on development of, 157
factors that affect causation of, 154
indications for penetrating keratoplasty, 148, 148
initial treatment, 163, 164
juvenile, 163
leading cause of irreversible blindness, 154, 162
lens-induced, 161, 163
phacomorphic, phacolytic, 163
profile of patients with, 164
mechanisms in enucleated retinoblastoma eyes 127
medications
administration with preservative-free dispenser, 140
neovascular, development in RB, 127
number of Filipinos with, 162
number of Filipinos with visual impairment due to,
154
number of people affected, 162
normal tension, 163
open-angle
IOP lowering with latanoprost, timolol, 83
pigmentary, 181
prevalence rates in selected countries, 162
primary angle-closure
compared with POAG, 63-64
most common initial treatment for, 161
profile of patients with, 164
primary open-angle
association with
age, 156-157
aspirin use, 157
family history, 157
intraocular pressure, 158
sex, 157
smoking, 157
systemic diseases, 156-157
vertical cupping, 156
visual-fiueld loss, 156
incidence compared with PACG, 162
most common initial treatment for, 161
risk factors for, among Filipinos, 153
treatment with latanoprost, timolol, 82
profile of patients with, 164
profile of cases at a tertiary institution, 161
secondary, 163
secondary to retinoblastoma, 124, 125
common mechanisms, 124
management, 127
suspects , 163-165
worldwide incidence, 154
Glaucomatous optic neuropathy 154-156, 163
Glycosylated hemoglobin
association with diabetic retinopathy, 180
GON. See glaucomatous optic neuropathy
Goniotomy, 162
Graft dehiscence, 166
Granuloma
after conjunctival autograft, 170
Graves’ ophthalmopathy, 12-13, 15-16
H
HAIOL. See intraocular lenses, hydrophobic acrylic
Heart disease
association with POAG, 156
Heart rate
with use of tropicamide, phenylephrine, 7, 11
Helen Keller International, 97
Hypertension
association with POAG, 153, 156, 158
risk factor for glaucoma, 154
Hyperthermia
and TTT, 118
Hypotony
complication of uveitis, 40
I
Idiopathic pars planitis, 39
IFETB. See International Federation of Eye and Tissue
Banks
Infection
of eyelid
predisposing factor for preseptal cellulitis, 32
Infectious keratitis
fungal etiology, 150
Inflammation
in rabbit eyes treated with chlorhexidine, 121
of cornea resulting from the application of
chlorhexidine gluconate, 123
Institute of Ophthalmology, 97
International Federation of Eye and Tissue
Banks, 146
International Uveitis Study Group, 38
Intraocular lens
anterior-chamber, 182
hydrophobic acrylic, implantation in the ciliary
sulcus, 181-182
association with PDS and PG, 183-184
implantation for aphakic correction, 182
in-the-bag implantation with phacoemulsification, 65
iris-fixated, 183
polymethylmethacrylate, 182
power estimation, 25, 27
Intraocular pressure
association with glaucoma, POAG, 156-158
elevated
complication of orbital and preseptal cellulitis, 32
risk factor for POAG, 154
increase in retinoblastoma, 125, 127
lowering
agents for, 162
effect on glaucoma incidence, progression, 158
measurement, as screening tool for glaucoma, 154
reduction with latanoprost, timolol, 83
transient rise, 182
uncontrolled, 163
Intraretinal microvascular abnormality, 179
Intravenous methylprednisolone
Side effects of, 71
treatment for optic neuritis 68-69
versus oral prednisone for optic neuritis, 67
visual outcomes in optic-neuritis patients, 70
IOL. See intraocular lens
IOP. See intraocular pressure
Iris
neovascularization
association with retinoblastoma, 125
factors leading to, 126
in retinoblastoma
diagnosis, 128
pigmentation with latanoprost use, 84
pigmented, chafing of, 184
Ischemia
risk factor for POAG, 154
IVMP. See methylprednisolone, intravenous
K
Keratitis
treatment with chlorhexidine, 122-123
Keratoconjunctivitis sicca, 21
Keratoconus
indication for PKP, 148-151
Keratometer, 25
Keratomycosis
cause of ocular morbidity, 120
difficulty of cure, 120
treatment with chlorhexidine gluconate, 119
Keratopathy, 21
L
Laser
iridotomy, 162
iridoplasty, 162
trabeculoplasty, 162
photocoagulation
for intraocular retinoblastoma, 78
Laser in situ keratomileusis
complications and side effects, 77
for myopia correction, 75, 77
safety and efficacy, 76
Laser-assisted in situ keratomileusis, 35
LASIK. See Laser in situ keratomileusis
Latanoprost
IOP lowering with, 83
compared with timolol
for POAG, 82
randomized controlled trial, 83
Lens extraction, 163
Leukostasis
caused by TTT, 118
Levator, 13
Levator aponeurosis, 12
Lid retraction
causes of, 13
in patients with Grave’s ophthalmology, 12
Linezolid
compared with other other antibiotics, 173
described, 173
effects on ERG, 175
histopathologic changes with, 175, 176
safety of intravitreal injection, 172
M
Macular degeneration, 182
Macular edema
postoperative progression in diabetic patients, 63
Macular Photocoagulation Study, 116
Mean defect
association with POAG 153, 156
Membrane
human amniotic
processing of, 167
transplantation of, 167
Metamorphopsia
in RPED, 116
Microaneurysms, 179
Microbial keratitis
age distribution of cases, 151
association with trauma, 151
indication for PKP, 148, 149, 150
leading to corneal perforation, 21
Migraine
association with POAG, 156, 158
risk factor for glaucoma, 154
Mitomycin C
adjuvant treatment for excision of primary
pterygium, 88
Moorfields Macular Study Group, 116
Moxifloxacin
intravitreal injection of, 19
retinal toxicity of, 17, 18
side effects of systemic use, 19
Muller muscle
overaction, 13
recession
for mild to moderate upper-eyelid retraction, 12-16
Multifocal choroiditis 39
Multiple sclerosis
development of, 72
development after treatment of optic neuritis with
IVMP and oral prednisone, 70-71
similarity of MRI findings with optic neuritis, 68
Mydriasis, 8
Myopia
and POAG prevalence, 154
association with POAG, 157
correction with laser, 75
correction with LASIK, 77
relationship to glaucoma, 156
N
N-Butyl-2-cyanoacrylate
bonding strength of, 20, 23
use in sealing corneal perforations, 21
leaking pressure, leak incidence, 22
Natamycin
compared with chlorhexidine, 120
National Society for the Prevention of Blindness, 5
Neovascular-membrane morphology, 54
Neovascularization
classic choroidal, 53
due to ARMD, 47
occult choroidal, 52
of the iris, in glaucoma secondary to retinoblastoma,
124
subfoveal choroidal, 50
NVI. See iris neovascularization
Nylon 10-0
bonding strength of, 20
O
ONH. See optic-nerve head
ONTT. See Optic Neuritis Treatment Trial
Ophthalmological Society of the Philippines 5
Ophthalmology
development as a separate specialty, 5
organized, history in the Philippines, 4
pillars of Philippine, 98
Optic cupping
association with POAG, 156
Optic disc
vertical cupping
association with POAG, 153
Optic nerve
disorder of, 68
involvement in RB with secondary glaucoma, 127
Optic-nerve head
structural changes, association with POAG, 154
parameters, association with glaucoma, 158
Optic neuritis
common presentation, 68
complication of uveitis, 40
monosynaptic, 68
recovery of vision, 71
recurrence, 67, 71
recurrence after treatment
with IVMP, 70
oral prednisone, 70v treatment with steroids, 67- 68
Optic Neuritis Treatment Trial, 68-71
Optic neuropathy
glaucomatous, 154
Orbit
cholesterol granuloma of, 129
P
PACG. See glaucoma, primary angle-closure
Pain
acute, symptom of glaucoma, 164
comparison in amniotic-membrane allograft and
conjunctival autograft, 170
Panuveitis, 37, 39
Pars plana vitrectomy, 162
treatment for endophthalmitis, 137
Pattern standard deviation
association with POAG, 153, 156-157
PBK. See pseudophakic bullous keratopathy
PCR. See posterior-capsule rupture
PDS. See pigment-dispersion syndrome
PDT. See photodynamic therapy
Penetrating keratoplasty
leading indications for, 148
leading indications in developed world, 150
leading indications in developing countries, 150
main indications for, 149
Phacoemulsification
progression of diabetic retinopathy after, 65
effect on progression of diabetic retinopathy, 62
posterior-capsule rupture during, 181
prevention of endophthalmitis after, 86
review of clinical-practice guidelines, 91-92
stop-and-chop, 182
worldwide implementation, 44
Phenylephrine
adverse systemic reactions 8
cardiovascular actions of, 8
combined with tropicamide
pressor and mydriatic effects, 7
dilation per unit time, 11
mydriatic effect, 10
Philippine Ophthalmological and Otolaryngological
Society, 5
Philippine Academy of Ophthalmology, 4, 6
Philippine Academy of Ophthalmology and
Otolaryngology, 5
Philippine Board of Ophthalmology, 6
Philippine Board of Ophthalmology and
Otolaryngology, 5
Philippine Eye Bank for Sight Restoration, 5
Philippine Eye Research Institute, 97
Philippine Journal of Ophthalmology, 5
Philippine Journal of Ophthalmology and
Otolaryngology, 5
Philippine Society of Ophthalmology, 5
Photodynamic therapy
adverse effects, 55
cost-effectiveness, 59
for neovascular ARMD, 46
implications for health services, 60
in people with choroidal neovascularization, 47
prevention of visuall loss, 59
with verteporfin versus placebo, 51, 52
with verteporfin, economic benefits, 59
Photodynamic therapy study (TAP), 116
Pigment-dispersion syndrome
incidence after HAIOL implantation, 182
Pigmentary glaucoma
incidence after HAIOL implantation, 182
PKP. See penetrating keratoplasty
PMMA. See intraocular lens, polymethylmethacrylate
POAG. See primary open-angle glaucoma
Posterior-capsule rupture, 181-183
Povidone-iodine
for prevention of postoperative endophthalmitis, 86
Prednisone
oral
tretment for optic neuritis, 69
versus intravenous methylprednisolone, 67
Proptosis, 15
in orbital cellulitis, 30
Prostaglandin analogs, 162
Pseudophakia, 183
Pseudophakic bullous keratopathy
indication for PKP, 148-151
age distribution of cases, 151
peak of incidence, 151
Pterygium
use of dehydrated human-amniotic-membrane
allograft versus conjunctival autograft after
excision, 167-171
prevention of recurrence, 88
primary, surgical interventions for, 88
risk of recurrence, 89
surgical treatment options, 88
technique of excision, 168
Pupil
changes in size
after administration of tropicamide 0.5% +
phenylephrine, 10-11
dilation with phenylephrine, tropicamide, 8
size determination, 34
using digital camera, 35
with infrared video camera, 35
Pupillary block
mechanism of glaucoma in retinoblastoma, 127
angle closure due to, 163
R
RB. See retinoblastoma
Reepithelialization
in rabbit eyes after chlorhexidine administration, 119
Refraction
association with POAG, 156
Refractive error
association wit POAG, 157
Refractive surgery
Safety and efficacy, 77
Regraft
indication for PKP, 148-151
rate of, 151
Republic Act 7885, 146
Retina
scarring, 47
signs associated with ARMD, 47
Retinal detachment
complication of uveitis, 38, 40
Retinal pigment epithelium, 47
proliferation caused by TTT, 118
reduction in size after TTT, 117
Retinal toxicity, 172
Retinal-pigment epithelial detachment
associated with ARMD, 117
clinical course of, 117
consequences of, 116
in neovascular age-related magular degeneration, 116
treatment with TTT, 115, 118
Retinoblastoma
association with secondary glaucoma, 125
clinical trials in the treatment of, 79
in children manifesting at older age, 127
intraocular
globe-sparing interventions, 78
with seconday glaucoma, 124
Retinopathy of prematurity
association with iris neovascularization, 127
Rosenbaum chart, 35
Rosenbaum-pupil-comparison, 34
RPE. See retinal pigment epithelium
RPED. See retinal-pigment epithelial detachment
S
Santa Lucia International Eye Bank of Manila, 145-146
Scanning Laser Ophthalmoscope, 53
Sclerosis
caused by TTT, 118
Sentro Oftalmologico Jose Rizal, 147
Serum-creatinine
correlation with diabetic retinopatthy, 180
Sex
association with POAG, 157
Sight
importance of, 4
Silicone polypropylene foldable lenses
association with endophthalmitis, 138
Sinus
involvement in orbital cellulitis, 31
Sinusitis
association with orbital and preseptal cellulitis, 32
SLIEB. See Santa Lucia International Eye Bank
Small-incision sutureless cataract surgery, 45
Smoking
association with
diabetic retinopathy, 180
POAG, 156
Sta. Lucia International Eye Bank Foundation, 148
Staphylococcus sp.
involvement in orbital and preseptal cellulitis, 32
Steroid
association with POAG, 156
treatment for optic neuritis, 68
Steven Johnson Syndrome, 149
Subretinal neovascular membranes, 47
Surell’s formula
for computing axial length, 24, 27
for computation of IOL power, 25
Surgery
for orbital and preseptal cellulitis, 33
T
TAP 1999, 49-55, 56, 58, 116
Tarsorrhaphy
lateral, 13
for management of Graves’ophthalmopathy, 15
Tenon’s capsule, 168
Thermotherapy
for treatment of intraocular tumors, 81
Thyroid disease
association with POAG, 156, 158
risk factor for glaucoma, 154
Timolol
compared with latanoprost
for POAG, 82
randomized controlled trial, 83
IOP lowering in POAG, 83
Toxicity
of chlorhexidine on the cornea, 119
Toxocara
cause of uveitis, 40
Toxoplasma
cause of uveitis, 40
Trabeculectomy, 162-163
Transpupillary thermotherapy
association with vascular thrombosis, 118
described, 118
for neovascular ARMD, 116
for retinal-pigment epithelial detachment, 115, 118
for retinoblastoma, 78
techniques of, 116
described, 118
Trauma
association with microbial keratitis, corneal scar, 151
association with orbital and preseptal cellulitis, 32
cause of corneal lacerations, 21
incidence among males, 151
indication for PKP, 149, 151
Tropicamide
cardiovascular actions of, 8
combined with phenylephrine
pressor and mydriatic effects, 7, 10
dilation per unit time, 11
TTT. See transpupillary thermotherapy
Tuberous sclerosis
description, 141
diagnosis, 141
ophthalmic features of, 141
Tumor
Intraocular, 78
See also retinoblastoma
U
Ultrasound, 25
Upper-eyelid retraction
in Graves’ ophthalmopathy, 13
secondary to Graves’ disease, 12, 15
Uveitis
age at presentation, 40
association with ACIOL, 183
changes in patterns over time, 40
cause of blindness, 41
defined, 38
endogenous
defined, 38
distribution and clinical characteristics, 37
etiologies, 39
idiopathic anterior, 39
infectious causes, 40
ocular complications and blindness, 37
patterns in a Philippine eye clinic, 37
profile among Filipino patients, 39
profile of Filipino patients with, 38
sight-threatening complications, 38, 40, 41
systemic medication for, 40
treatment, 38
with immunosuppressive drugs, 41
tuberculous, 40
V
Vacuolization, 175-176
Vancomycin
caution against routine use for prophylaxis, 87
for prevention of postoperative endophthalmitis, 86
treatment for endophthalmitis, 138
Vascular thrombosis
caused by TTT, 118
Verteporfin
safety and effectiveness, 50
in photodynamic therapy study, 116
Vertical cupping
association with POAG, 153, 156-157
Videoangiography
fluorescein
diagnostic adjunct in RPED, 118
indocyanine green, 116
sodium, 116
VIP 2001, 49, 50-58, 116
Viral infection
indication for PKP, 150-151
Vision
loss in
ARMD, 47
untreated PACG, 163
Visual acuity
association with POAG, 153, 156-157
change after TTT, 115, 117
relationship to glaucoma, 156
decrease with PDT, 59
Visual field
mean defect
association with POAG, 156
pattern standard deviation
association with POAG, 156-157
Visudyne, 50
Vitreous hemorrhage
complication of uveitis, 38, 40
Vogt-Koyanagi-Harada syndrome
diagnosis and treatment, 134
diagnostic criteria, 134
etiology and pathogenesis, 134
stages, 135
treatment, 135